Allyl chloride | CAS:107-05-1

We serve Allyl chloride CAS:107-05-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Allyl chloride

Chemical Name:Allyl chloride
CAS.NO:107-05-1
Synonyms:Allyl chloride
3-Chloro-1-propene
prop-2-en-1-yl 3-oxobutanoate
allyl 3-ketobutanoate
2-propenyl acetoacetate
 
Physical and Chemical Properties:
Density 0.9±0.1 g/cm3
Boiling Point 41.6±9.0 °C at 760 mmHg
Melting Point -136 °C
Molecular Formula C3H5Cl
Molecular Weight 76.525
Flash Point -28.9±0.0 °C
Vapour density 2.6 (vs air)
Vapour Pressure 416.7±0.1 mmHg at 25°C
Index of Refraction 1.401
 
Specification:
Appearance:Colourless to light yellow liquidAssay:≥98.0%
Moisture:≤1.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Molosultap(CAS:52207-48-4) and Cartap(CAS:15263-53-3).



Contact us for information like Allyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-propenyl acetoacetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-propenyl acetoacetate Use and application,Allyl chloride technical grade,usp/ep/jp grade.


Related News: Such was the apparent demand sparked by the notice that the compound formula sold out on some stores on China’s e-commerce platform Taobao.(1R,2S)-1-tert-Butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid manufacturer Such was the apparent demand sparked by the notice that the compound formula sold out on some stores on China’s e-commerce platform Taobao.Siloxanes and Silicones, Me 3,3,3-trifluoropropyl, Me vinyl, hydroxy-terminated supplier As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.3-(diethylamino)phenol,sulfuric acid vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.